The data came from a phase 3 trial that enrolled 29,960 participants across 119 sites in the U.S. and Mexico. Novavax said it recruited participants from the communities and demographic groups most affected by COVID-19.
Should the vaccine be cleared by the FDA, Novavax is ready to manufacture 150 million doses each month by the end of 2021.
